血浆钼水平升高通过血管内皮损伤增加早发性卵巢功能不全风险
病例对照研究纳入30例特发性早发性卵巢功能不全(POI)患者和31例对照,发现血浆钼和钙浓度升高与POI比值比正相关;体外实验显示钼增加人脐静脉内皮细胞通透性并抑制颗粒细胞增殖,小鼠体内实验显示钼诱导血管通透性增加、血小板活化和血清素释放,最终导致卵巢功能障碍。
要点
- 血浆钼和钙浓度升高与特发性POI的比值比呈正相关。
- 钼通过增加一氧化氮生成和胞质钙内流增加血管内皮通透性。
- 钼诱导的血管通透性增加导致小鼠卵巢内血小板活化和血清素释放,抑制颗粒细胞增殖。
核心结论
- 血浆钼水平升高与特发性POI风险增加相关,机制涉及血管内皮损伤和抑制颗粒细胞增殖。
研究设计与样本
- 病例对照研究纳入30例特发性POI患者和31例对照,招募时间为2018年8月至2019年5月,两组年龄和体重指数可比。
- 体外实验使用人脐静脉内皮细胞和KGN(人卵巢颗粒样肿瘤细胞系)细胞。
- 动物实验使用含钼酸钠的蒸馏水暴露小鼠。
主要发现
- 病例对照研究显示血浆钼和钙浓度升高与POI比值比正相关。
- 体外实验显示钼处理通过增强一氧化氮生成和胞质钙内流增加人脐静脉内皮细胞通透性。
- 体内实验显示钼诱导的血管通透性增加导致小鼠卵巢内血小板活化和血清素释放。
- 血清素通过诱导细胞静止降低颗粒细胞增殖,钼还通过下调异柠檬酸脱氢酶(IDH1)直接抑制颗粒细胞增殖。
- 抑制颗粒细胞增殖最终导致小鼠卵巢功能障碍,包括动情周期、血清性激素浓度、卵巢形态和卵巢储备改变。
局限性
- 目前尚不清楚血浆钼含量升高是由于环境暴露还是代谢改变。
- 需要开展更大样本量的严格多中心研究来证实特发性POI患者血浆钼和钙浓度升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is elevated plasma molybdenum level associated with increased risk for idiopathic premature ovarian insufficiency (POI)? SUMMARY ANSWER: Elevated plasma molybdenum level is associated with an increased risk of idiopathic POI through vascular endothelial injury and inhibition of granulosa cell proliferation. WHAT IS KNOWN ALREADY: Excessive molybdenum exposure has been associated with ovarian oxidative stress in animals but its role in the development of POI remains unknown. STUDY DESIGN, SIZE, DURATION: Case-control study of 30 women with idiopathic POI and 31 controls enrolled from August 2018 to May 2019. In vitro experimentation. Animal studies using distilled water containing sodium molybdate. PARTICIPANTS/MATERIALS, SETTING, METHODS: Logistic regression analysis of the association between plasma concentrations of molybdenum and calcium and POI odds ratio. Plasma samples were from 30 patients with idiopathic POI and 31 controls. Both groups were comparable in terms of age and body mass index. Proliferation assay, flow cytometry analyses for cell cycle, nitric oxide and calcium, gene expression, and protein analysis using human umbilical vein endothelial cells and KGN (human ovarian granulosa-like tumor cell line) cells. Sexual hormones, ovarian function, vascular injury, and platelet activation were evaluated in mice exposed to excessive molybdenum. MAIN RESULTS AND THE ROLE OF CHANCE: Case-control study showed that the elevation of plasma concentrations of molybdenum and calcium was positively associated with the POI odds ratio. In vitro study showed that molybdenum treatment increased the permeability of human umbilical vein endothelial cells through enhancing nitric oxide generation and cytosolic calcium influx. In vivo study showed that increased vascular permeability induced by molybdenum resulted in platelet activation and serotonin release within mouse ovaries. Serotonin decreased granulosa cell proliferation by inducing cellular quiescence. Molybdenum also directly inhibited granulosa cell proliferation by downregulating isocitrate dehydrogenase (IDH1). Inhibition of granulosa cell proliferation ultimately led to ovarian dysfunction in mice, including altered estrus cycles, serum sex hormone concentrations, ovarian morphology, and ovarian reserve. LIMITATIONS, REASONS FOR CAUTION: There are two limitations in the current study. First, it remains unclear whether the elevation of plasma molybdenum content is due to environmental exposure or altered metabolism. Second, rigorous and multicenter studies, with a larger sample size, should be carried out to confirm the elevation of plasma molybdenum and calcium concentrations in patients with idiopathic POI. WIDER IMPLICATIONS OF THE FINDINGS: Our findings highlight an association between elevated plasma concentrations of molybdenum and calcium and increased risk of idiopathic POI. This discovery offers crucial insights into the pathogenesis of idiopathic POI and the search for effective preventive measures. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the National Natural Science Foundation of China (82271664), the interdisciplinary program of Shanghai Jiao Tong University (YG2022ZD028), the Research Projects of Shanghai Municipal Health Committee (202240343), and Shanghai Clinical Research Center for Cell Therapy (23J41900100). None of the authors has any conflict of interest to disclose. TRIAL REGISTRATION NUMBER: N/A.
引用
- Wang L, Wang Q, Sun J, et al. Elevated plasma molybdenum level increases the risk of premature ovarian insufficiency through vascular endothelial injury. Hum Reprod. 2025. PMID: 39761515. doi:10.1093/humrep/deae297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。